Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 52: 1528-1538, 2006. First published June 15, 2006; 10.1373/clinchem.2006.069575
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.069575v1
52/8/1528    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Masson, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Masson, S.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2006;52:1528-1538.)
© 2006 American Association for Clinical Chemistry, Inc.


Lipids, Lipoproteins, and Cardiovascular Risk Factors

Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data

Serge Masson1,a, Roberto Latini1,2, Inder S. Anand3, Tarcisio Vago4, Laura Angelici1, Simona Barlera1, Emil D. Missov5, Aldo Clerico6, Gianni Tognoni7, Jay N. Cohn5 on behalf of the Val-HeFT Investigators

1 Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
2 Department of Medicine, New York Medical College, Valhalla, NY.
3 Cardiology Section, Veterans Affairs Medical Center, Minneapolis, MN.
4 Laboratorio di Endocrinologia, Ospedale "Luigi Sacco", Milan, Italy.
5 Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN.
6 Laboratory of Cardiovascular Endocrinology and Cell Biology, Consiglio Nazionale delle Ricerche, Institute of Clinical Physiology, Pisa, Italy.
7 Consorzio Mario Negri Sud, S. Maria Imbaro, Chieti, Italy.

aAddress correspondence to this author at: Istituto di Ricerche Farmacologiche "Mario Negri", via Eritrea 62, 20157 Milan, Italy. Fax 39-023-320-0049; e-mail masson{at}marionegri.it.

Background: The B-type or brain natriuretic peptides (BNP) and the amino-terminal probrain natriuretic peptide (NT-proBNP) are good markers of prognosis and diagnosis in chronic heart failure (HF). It is unclear, however, whether differences in their biological characteristics modify their clinical correlates and prognostic performance in HF. This work aimed to provide a direct comparison of the prognostic value of BNP and NT-proBNP in patients with chronic and stable HF.

Methods: We measured BNP and NT-proBNP at baseline in 3916 patients enrolled in the Valsartan Heart Failure Trial. To identify the variables associated with both peptides, we conducted simple and multivariable linear regression analyses. We used Cox multivariable regression models to evaluate the independent prognostic value for all-cause mortality, mortality and morbidity, and hospitalization for HF. Prognostic performance was assessed by pairwise comparisons of the area under the curve of receiver-operator characteristic curves.

Results: NT-proBNP and BNP had similar relationships with age, left ventrical ejection fraction, and internal diameter and creatinine clearance. Either peptide ranked as the first independent predictor of outcome after adjustment for major confounding clinical characteristics. ROC curves were almost superimposable for all-cause mortality (area under the curve (SE): BNP 0.665 (0.011) vs NT-proBNP 0.679 (0.011); P = 0.0734), but NT-proBNP was superior to BNP for predicting mortality and morbidity (P = 0.032) or hospitalization for HF (P = 0.0143). Overall sensitivity and specificity ranged from 0.590 to 0.696.

Conclusions: The natriuretic peptides BNP and NT-proBNP showed subtle differences in their relation to clinical characteristics and prognostic performance in a large population of patients with chronic and stable HF. They were the most powerful independent markers of outcome in HF.




The following articles in journals at HighWire Press have cited this article:


Home page
J Am Coll CardiolHome page
S. Masson, R. Latini, I. S. Anand, S. Barlera, L. Angelici, T. Vago, G. Tognoni, J. N. Cohn, and for the Val-HeFT Investigators
Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial)
J. Am. Coll. Cardiol., September 16, 2008; 52(12): 997 - 1003.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. M. Richards
Serial Measurements of Plasma B-Type Natriuretic Peptides: What Do They Tell Us?
J. Am. Coll. Cardiol., September 16, 2008; 52(12): 1004 - 1005.
[Full Text] [PDF]


Home page
Ann Clin BiochemHome page
E. C H J Michielsen, J. A Bakker, R. R J V. Kimmenade, Y. M Pinto, and M. P V. Dieijen-Visser
The diagnostic value of serum and urinary NT-proBNP for heart failure
Ann Clin Biochem, July 1, 2008; 45(4): 389 - 394.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. Vickery, M. C. Webb, C. P. Price, R. I. John, N. A. Abbas, and E. J. Lamb
Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population
Nephrol. Dial. Transplant., June 18, 2008; (2008) gfn341v1.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. Braunwald
Biomarkers in Heart Failure
N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159.
[Full Text] [PDF]


Home page
CJASNHome page
R. Paniagua, D. Amato, S. Mujais, E. Vonesh, A. Ramos, R. Correa-Rotter, and W. H. Horl
Predictive Value of Brain Natriuretic Peptides in Patients on Peritoneal Dialysis: Results from the ADEMEX Trial
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 407 - 415.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Schou, F. Gustafsson, C. N. Kistorp, P. Corell, A. Kjaer, and P. R. Hildebrandt
Effects of Body Mass Index and Age on N-Terminal Pro Brain Natriuretic Peptide Are Associated with Glomerular Filtration Rate in Chronic Heart Failure Patients
Clin. Chem., November 1, 2007; 53(11): 1928 - 1935.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
C. R. deFilippi, S. L. Seliger, S. Maynard, and R. H. Christenson
Impact of Renal Disease on Natriuretic Peptide Testing for Diagnosing Decompensated Heart Failure and Predicting Mortality
Clin. Chem., August 1, 2007; 53(8): 1511 - 1519.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Omland, M. S. Sabatine, K. A. Jablonski, M. M. Rice, J. Hsia, R. Wergeland, S. Landaas, J. L. Rouleau, M. J. Domanski, C. Hall, et al.
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial
J. Am. Coll. Cardiol., July 17, 2007; 50(3): 205 - 214.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. Tsutamoto, T. Tanaka, H. Sakai, C. Ishikawa, M. Fujii, T. Yamamoto, and M. Horie
Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure
Eur. Heart J., July 2, 2007; 28(14): 1723 - 1730.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
B. Assmus, U. Fischer-Rasokat, J. Honold, F. H. Seeger, S. Fichtlscherer, T. Tonn, E. Seifried, V. Schachinger, S. Dimmeler, and A. M. Zeiher
Transcoronary Transplantation of Functionally Competent BMCs Is Associated With a Decrease in Natriuretic Peptide Serum Levels and Improved Survival of Patients With Chronic Postinfarction Heart Failure: Results of the TOPCARE-CHD Registry
Circ. Res., April 27, 2007; 100(8): 1234 - 1241.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.